Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026

Alcon announced the U.S. launch of Clareon TruPlus, its new enhanced design monofocal and toric intraocular lens (IOL), at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. TruPlus expands Alcon’s leading Clareon portfolio, offering surgeons an enhanced design IOL, enabling increased depth of focus without compromising the high-quality distance vision they expect from a monofocal IOL.^1,2

Based on bench data, TruPlus has a number of differentiating features over Clareon Monofocal and the leading competitor IOL:⁴

• TruPlus demonstrates a 3.5 letter improvement in simulated visual acuity at -1.5 diopters (66 cm) compared to Clareon Monofocal ^1,†
• TruPlus offers higher distance image quality than TECNIS Eyhance across a range of pupil sizes and lighting conditions ^3,*
• TruPlus exceeds the ISO upper requirement for distance image quality ^1,2,5
• TruPlus demonstrates a lower glare and halo profile than TECNIS Eyhance ^3,6,*

Designed for Surgeons, Built for Patients

“Cataract surgeons naturally want to offer patients a little more — without trade-offs,” said Terry Kim, M.D., Chief Medical Officer at Alcon. “Surgeons told us they were looking for an enhanced design monofocal that did not sacrifice distance vision quality. TruPlus was developed to address that need, while maintaining the exceptional stability and clarity that define the proven Clareon platform.”

TruPlus leverages proprietary Opti-Balance Technology in the center of the lens to slightly extend the depth of focus.⁷ This innovative design boosts light energy for an increased depth of focus, while maintaining exceptional distance image quality and a wide refractive landing zone.^7,8

With more than 175 million IOLs implanted globally, Alcon is a leader in cataract surgery.^9,+ TruPlus joins Alcon’s broad portfolio of Clareon IOLs that includes the number one monofocal; Vivity, the leading extended depth of focus IOL; PanOptix Pro and PanOptix, the world’s most implanted trifocal IOL.^{4,10–12,‡,±} TruPlus will launch in additional markets later this year. For more information about the latest addition to Alcon’s IOL portfolio, visit MyAlcon.com or the Alcon booth (#943) during ASCRS.

_{* Trademarks are the property of their respective owners.}

_{† Based on bench Modulation Transfer Function (MTF) simulated defocus curve.}

_{+ Based on unit sales of Alcon IOLs from 1993 through January 2026.}

_{‡ Based on worldwide IOL unit sales, Q1-Q3, 2025.}

_{± Based on worldwide IOL unit sales of AcrySof IQ Vivity and Clareon Vivity IOLs, through Q3, 2025.}

_References

1. _{Alcon data on file, 2025. [REF-28331].}
2. _{Alcon data on file, 2025. [REF-28335].}
3. _{Alcon data on file, 2025. [REF-28549].}
4. _{MarketScope LLC. 2025 IOL Market Report: Global Analysis for 2024 to 2030. St. Louis, MO: MarketScope LLC; 2025.}
5. _{Alcon data on file, 2025. [REF-28362].}
6. _{Alcon data on file, 2025. [REF-28699].}
7. _{Alcon data on file, 2026. [REF-28847].}
8. _{Alcon data on file, 2025. [REF-28698].}
9. _{Alcon data on file, 2026. [REF-29048].}
10. _{Alcon data on file, 2025. [REF-28420].}
11. _{Alcon data on file, 2025. [REF-28305].}
12. _{MarketScope LLC. 2025 Premium Cataract Surgery Market Report: Analysis of the Top 13 Markets for 2024 to 2030. St. Louis, MO: MarketScope LLC; 2025.}